Previous 10 | Next 10 |
BEDMINSTER, N.J., March 01, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to present a Company overview at the Barclays Global Healthcare Conference on Tuesday, March 9, 2021...
Shares of Matinas BioPharma Holdings (NYSEMKT: MTNB) were crashing 32.7% lower as of 3:01 p.m. EST on Monday. The steep decline came after the company announced disappointing results from a phase 2 clinical study of Lypdiso in reducing triglycerides. Matinas had good news and ba...
Gainers: Comstock Mining (LODE) +125%.Viela Bio (VIE) +53%.Dynavax Technologies (DVAX) +47%.Avino Silver & Gold Mines (ASM) +46%.Ferroglobe (GSM) +43%.Alithya (ALYA) +39%.Tuscan Holdings (THCB) +35%.Sundial Growers (SNDL) +32%.Inovio Pharmaceuticals (INO) +31%.Bio...
Matinas BioPharma (MTNB) announces topline results from the ENHANCE-IT study, the second comparative study of Lypdiso vs. Vascepa. The primary endpoint was the percent change from baseline to end-of-treatment in triglycerides (TGs) and superiority vs. Vascepa. Analyses were performed on ...
– LYPDISO ™ demonstrated a statistically significant 46% relative percent increase in EPA change from baseline over Vascepa ® – – LYPDISO ™ demonstrated a 39% relative difference in response over Vascepa in TG reduc...
Matinas has an OM3 drug that has demonstrated a superior profile to Amarin's Vascepa. It has a platform and, unlike Amarin, a diverse pipeline. I hope the company will learn from Amarin's mistakes and ensure proper protection for its IP moat. For further details see: Mat...
BEDMINSTER, N.J., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to present a Company overview at the ICR Conference 2021 on Thursday, January 14, 2021 at 1:00 p....
Aileron Therapeutics (ALRN) +73%.Broadway Financial Corporation (BYFC) +55% after regulatory approvals for merger with CFBanc Corporation.Atlantic American Corporation (AAME) +43%.Marker Therapeutics (MRKR) +30% after FDA lifted the partial clinical hold on it's Phase 2 trial.Cyclo ...
Shares of clinical-stage company Matinas BioPharma Holdings (NYSEMKT: MTNB) increased a robust 27.9% on Monday, following news that it won a crucial nod from the Food and Drug Administration. Matinas said Monday that it received conditional approval from the FDA for the brand na...
2 Analysts Think These Are Penny Stocks To Buy In this article, I’ll discuss a few penny stocks analysts have rated a buy. We’ll also discuss price targets issued and what recent events could be important if these are on your watch list right now. Keep in mind that...
News, Short Squeeze, Breakout and More Instantly...
Matinas Biopharma Holdings Inc. Company Name:
MTNB Stock Symbol:
NYSE Market:
Matinas Biopharma Holdings Inc. Website:
BEDMINSTER, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces the recent successful...
BEDMINSTER, N.J., June 13, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that MAT2203, its ora...
BEDMINSTER, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces new in vitro data ...